Back to top
more

Adaptive Biotechnologies (ADPT)

(Delayed Data from NSDQ)

$10.33 USD

10.33
1,710,864

+0.09 (0.88%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of +28.76% and +11.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Equity Research

What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Zacks Equity Research

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

by Zacks Equity Research

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.

Zacks Equity Research

U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot

by Zacks Equity Research

The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.

Zacks Equity Research

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FYC

Zacks Equity Research

Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.

Zacks Equity Research

Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for FYC

Zacks Equity Research

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz

by Zacks Equity Research

BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.

Zacks Equity Research

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer

by Zacks Equity Research

Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.

Zacks Equity Research

Allogene's Q1 Earnings In Line With Estimates, Sales Nil

by Zacks Equity Research

ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.

Zacks Equity Research

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

by Zacks Equity Research

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

by Zacks Equity Research

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.

Zacks Equity Research

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

by Zacks Equity Research

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

Zacks Equity Research

Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

by Zacks Equity Research

Here is how Adaptive Biotechnologies (ADPT) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 11.54% and 2.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?